Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 8/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13088381 | 0.92 | SLC5A1 (0.45) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL3684207 | 0.89 | SLC5A2 (0.47) | SLC5A2SLC5A1 | |
| SCHEMBL3673113 | 0.84 | SLC5A1 (0.66) | SLC5A2SLC5A1NPC1RAB9AHPGD | |
| SCHEMBL3675840 | 0.83 | SLC5A1 (0.53) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| SCHEMBL12808186 | 0.82 | PPARA (0.40) | SLC5A2SLC5A1ALDH1A1HPGD | |
| Atigliflozin SCHEMBL13644156 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| Atigliflozin SCHEMBL14981898 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| Atigliflozin SCHEMBL13641405 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| Atigliflozin SCHEMBL874745 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1NPC1RAB9AACHE | |
| Atigliflozin SCHEMBL19276485 | 0.79 | SLC5A2 (0.66) | SLC5A2SLC5A1NPC1RAB9AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1964845-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| EP-1967523-B1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-08-11 | — | — | EP | disclosed |
| US-7666848-B2 | such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| US-7666848-B2 | such as 3-(4-Methoxy-phenyl)-1-[3-(3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-thiophen-2-yl]-propan-1-one; for use as antidiabetics | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-02-23 | — | — | US | disclosed |
| WO-2009138195-A2 | USE OF THIOPHENE GLYCOSIDE DERIVATIVES FOR PRODUCING MEDICAMENTS FOR TREATMENT OF HYPERTENSION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-11-19 | — | — | WO | disclosed |
| EP-1523488-B1 | NOVEL THIOPHENYLGLYCOSIDE DERIVATIVES, METHODS FOR PRODUCTION THEREOF, MEDICAMENTS COMPRISING SAID COMPOUNDS AND USE THEREOF | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-11-12 | — | — | EP | disclosed |
| EP-1967523-A1 | New thiophen glycoside derivatives, method for their manufacture, medicines containing these compounds and their application | Sanofi-Aventis Deutschland GmbH (DE) | 2008-09-10 | — | — | EP | disclosed |